Celgene Corporation announced on January 22, 2018, that it had entered into a definitive agreement to acquire Juno Therapeutics, Inc., a leading researcher in cancer therapeutics development.
According to Celgene, this acquisition promises to add to Celgene’s lymphoma research program, JCAR017, accelerate revenue diversification and position the company as an even more prominent presence in cellular immunotherapy.
The acquisition is expected to close in the first fiscal quarter of 2018, subject to regulatory approvals.
